Form 4: Vaccinex COO Elizabeth Evans Reports Stock Option Grant

Elizabeth Evans, Chief Operating Officer of Vaccinex, Inc., reports the acquisition of stock options.

Summary

• On March 22, 2024, Elizabeth E. Evans, the Chief Operating Officer of Vaccinex, Inc., filed a Form 4.
• The report details the acquisition of 1,341 stock options with an exercise price of $8.32, granted on March 20, 2024, and exercisable starting March 20, 2025.
• The filing also reflects existing stock options held by Evans with varying exercise prices and expiration dates.
• All figures in the Form 4 reflect the Issuer's 1-for-15 reverse stock split effected on September 25, 2023 and 1-for-14 reverse stock split effected on February 19, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a routine disclosure of stock option grants.

Positives

• The grant of stock options to the COO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.

Industry Context

Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to monitor the actions of company executives.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates

Keywords

Vaccinex, VCNX, stock options, Form 4, Elizabeth Evans, COO, insider trading